Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Cosmetic Dermatology|March 12, 2022
Submental fat reduction using sequential treatment approach with cryolipolysis and ATX-101H Ray Jalian, Rebecca Fitzgerald, Beta Bowen, et al.Archives of Physical Medicine and Rehabilitation|May 30, 2006
Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticityCatherine C Turkel, Beta Bowen, Jingyu Liu, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|June 11, 2021
Randomized, Placebo-Controlled Phase 1/2 Study to Determine the Appropriate ATX-101 Concentration for Reduction of Submental FatGreg J Goodman, Lynda J Spelman, Nicholas Lowe, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 19, 2019
Histological Analysis of the Effect of ATX-101 (Deoxycholic Acid Injection) on Subcutaneous Fat: Results From a Phase 1 Open-Label StudyPatricia S Walker, Daniel R Lee, Bryant A Toth, et al.Journal of Drugs in Dermatology : JDD|January 4, 2011
Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar linesKenneth R Beer, Charles Boyd, Rina K Patel, et al.Aesthetic Surgery Journal|February 22, 2021
Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE TrialsShannon Humphrey, Joel L Cohen, Ashish C Bhatia, et al.Plastic and Reconstructive Surgery|August 13, 2025
Improvement of Lower Facial Shape After Treatment With OnabotulinumtoxinA: Secondary Results From a Phase 2 Dose Escalation StudySteven Liew, Jason K Rivers, Shannon Humphrey, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|April 19, 2019
A Double-Blind, Placebo-Controlled, Phase 3b Study of ATX-101 for Reduction of Mild or Extreme Submental FatRichard G Glogau, Dee Anna Glaser, Valerie D Callender, et al.Journal of the American Academy of Dermatology|November 10, 2024
Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: Primary results from a randomized phase 2 studyJean Carruthers, Steven Liew, Jason K Rivers, et al.Aesthetic Surgery Journal|April 26, 2026
Longitudinal Computed Tomographic Evaluation of Mandibular Bone Morphology Following OnabotulinumtoxinA Treatment of Masseter Muscle Prominence: Results of a 12-Month, Repeat-Treatment, Placebo-Controlled Study in Healthy AdultsSanjay M Mallya, Paul Kostenuik, René Hopfinger, et al.Pageof 2